NASD · Healthcare · Biotechnology · USA
Halozyme Therapeutics Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Halozyme Therapeutics is a biopharmaceutical company developing drug delivery technologies to improve patient experiences. The company licenses its ENHANZE technology, which uses a proprietary enzyme to enable subcutaneous injection of drugs, to pharmaceutical partners including Roche, Takeda, and Pfizer. Halozyme also offers Hypercon and Surf Bio technologies, auto-injector devices, and commercializes proprietary products including Hylenex and XYOSTED.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Halozyme Therapeutics Inc stock.
Overvalued: intrinsic value $95.27 per share, market price $122.50, margin of safety -28.6% (as of 2026-10-19).
Discounting its cash flows at 9.2% (average of 2 methods) values the shares at $95.27; the price of $122.50 is 29% above that value.
Leak Score: 58/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
40 more in this industry show a wider margin of safety.
HALO is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.2% (average of 2 methods) values the shares at $95.27; the price of $122.50 is 29% above that value.
$95.27 per share (as of the 2026-10-19 close), against a market price of $122.50. That is a margin of safety of -28.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
58 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.